AN2 Therapeutics is a technology company.
AN2 Therapeutics has raised $12.0M across 1 funding round.
AN2 Therapeutics has raised $12.0M in total across 1 funding round.
AN2 Therapeutics has raised $12.0M in total across 1 funding round.
AN2 Therapeutics's investors include Mountain Group Partners.
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics based on boron chemistry to treat rare, chronic, and serious infectious diseases with high unmet needs, such as Chagas disease, melioidosis, and NTM lung disease caused by *M. abscessus*, alongside oncology targets.[1][2][3] Its lead candidate, AN2-502998, targets chronic Chagas disease—a parasitic infection affecting 6-7 million people worldwide, including 300,000 in the U.S.—by offering potential curative activity in preclinical models across species, including non-human primates, where current treatments like benznidazole and nifurtimox fail due to poor efficacy and side effects in the chronic phase.[3][4] AN2 serves patients in global health settings, particularly neglected tropical diseases, partnering with organizations like DNDi to accelerate development; it has initiated a Phase 1 trial for AN2-502998, expecting completion in H2 2025 and Phase 2 in 2026, demonstrating early clinical momentum.[3][4]
AN2 Therapeutics emerged from the legacy of Anacor's Neglected Diseases team, which raised over $80 million and discovered over a dozen compounds for diseases like malaria, tuberculosis, Chagas, African sleeping sickness, and leishmaniasis.[1] Co-founder Eric Easom, Chairman, President, and CEO, led that team and chaired the Infectious Disease Research Institute board from 2009-2013, bringing deep expertise in boron-based drug discovery.[1][3] The company's lead asset, AN2-502998 (formerly AN15368), originated at Anacor in collaboration with the University of Georgia and Wellcome funding, marking a pivotal moment in advancing boron chemistry from neglected diseases research to a focused pipeline.[4] This backstory reflects a shift from broad philanthropic discovery to a commercial biopharma entity committed to high-impact therapies.[1][2]
AN2 rides the wave of advances in neglected tropical disease (NTD) therapeutics, where climate change, migration, and diagnostics improvements are expanding awareness and urgency for treatments like those for Chagas—a vector-borne parasite disease increasingly relevant in non-endemic regions like the U.S. and Europe.[3][4] Timing aligns with post-pandemic focus on antimicrobial resistance and rare infections, bolstered by nonprofit-public partnerships (e.g., DNDi, Wellcome) that de-risk development for pharma.[1][3] Market forces favor boron-based innovation, as traditional antibiotics fail chronic phases of diseases like Chagas, creating opportunities for first-in-class cures amid a 50-year treatment drought.[4] AN2 influences the ecosystem by validating boron chemistry for NTDs and oncology, potentially inspiring spinouts in crop protection and animal health while accelerating access via collaborations.[1][3]
AN2 is poised for inflection with Phase 1 readout of AN2-502998 in H2 2025 and Phase 2 proof-of-concept in 2026, potentially validating its platform and attracting partnerships or funding amid rising NTD investment.[3][4] Trends like AI-driven discovery, climate-impacted infectious diseases, and gender-equitable R&D (per DNDi priorities) will shape its path, expanding boron applications to oncology and new indications.[1][3] Its influence may grow by bridging pharma and global health nonprofits, delivering cures that transform outcomes for millions—echoing its Anacor roots in high-unmet-need innovation.[1][2]
AN2 Therapeutics has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in November 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2019 | $12.0M Series A | Mountain Group Partners |